In addition, we noticed that many targets overexpressed in GBM samples of the 180 series were downregulated in long surviving patients, including RAB20, RAB34, SWAP70, CYFIP1, ARPC1B, ARPC2 and ARPC4. The dataset is certainly limited in size and further investigation integrating all clinical aspects should be conducted to determine whether deregulated macropinocytosis could be a predictive marker for clinical outcome of the patient. The gene discussed is ARPC2; the disease is glioblastoma.